Four Peptides That Have Anti-Cancer Potential
Most people discover peptides through fat loss, recovery, or skin health. But there is an emerging area of research that doesn't get talked about nearly enough — the role these compounds may play in cellular protection, DNA integrity, and tumor suppression.
None of these are cures. Most of the evidence comes from preclinical models and early-stage in vitro work. But the mechanisms being uncovered are genuinely fascinating — and they point to something important about how our biology maintains itself at the cellular level.
Here are four peptides researchers are watching closely, and what the data actually shows.
Most know Retatrutide as a next-generation obesity drug — a GLP-1/GIP/glucagon triple agonist that produces some of the most dramatic weight loss numbers seen in a Phase 2 trial.[1] But a 2025 study published in npj Metabolic Health and Disease by Marathe et al. extended the picture significantly.
The research found that cancer cells thrive in metabolic environments defined by chronic inflammation, insulin resistance, and immune suppression — all conditions that Retatrutide directly counteracts. In preclinical obesity models, RETA didn't just reduce weight: it fundamentally reshaped the tumor microenvironment.
In pancreatic cancer models, RETA reduced tumor engraftment, delayed tumor onset, and produced a 14-fold reduction in tumor volume compared to controls — versus only 4-fold for semaglutide. In a lung cancer model (not even considered obesity-associated), RETA achieved 50% reduced tumor engraftment and a 17-fold reduction in tumor volume.[2]
Notably, even when RETA was withdrawn and mice regained weight, the anti-tumor benefits persisted — suggesting the immune reprogramming it induced was durable beyond the drug's active presence.[2]
MOTS-c is a mitochondrially-encoded peptide — one of a small class of compounds now being called "mitokines," signaling molecules produced by mitochondria that influence whole-body metabolism. It works primarily through the AMPK pathway, signaling cells to prioritize repair, glucose metabolism, and stress adaptation over uncontrolled growth.[3]
What makes the cancer connection compelling is a pattern emerging across multiple cancer types: MOTS-c levels are consistently reduced in cancer patients. A 2024 study in Advanced Science found MOTS-c significantly reduced in both serum and tumor tissues from ovarian cancer patients, and that low MOTS-c expression was directly associated with poor prognosis.[4] When exogenous MOTS-c was introduced, it dose-dependently inhibited proliferation, migration, and invasion of cancer cells.
Reduced
Circulating Levels
MOTS-c disrupts purine synthesis by inhibiting the folate-methionine cycle, increasing AICAR — an AMPK activator — and redirecting cells away from the metabolic patterns that support tumor growth. Researchers note its mechanism shares similarities with methotrexate, a drug originally developed for cancer treatment.[3,4]
MOTS-c levels were significantly reduced in both serum and tumor tissues from ovarian cancer patients, and low expression was associated with poor prognosis. Exogenous MOTS-c dose-dependently inhibited cancer cell proliferation, migration, and invasion.
Yin et al., Advanced Science, 2024 — PMC11578304Epitalon is a synthetic tetrapeptide originally developed at the St. Petersburg Institute of Bioregulation and Gerontology, and it has one of the longest research histories of any peptide in this category. Its primary mechanism is the activation of telomerase — the enzyme that maintains and extends telomere length.[5]
Telomeres are the protective caps at the ends of chromosomes. As they shorten with each cell division, cells accumulate DNA damage and eventually become dysfunctional. This process is one of the primary drivers of aging-related disease — and a precondition for many cancers. Epitalon slows this decline by maintaining the cellular machinery that keeps telomeres intact.
A 2025 study published in Biogerontology demonstrated that Epitalon produced dose-dependent telomere length extension in human cell lines. In normal healthy cells, this occurred via telomerase upregulation; in breast cancer cell lines, via ALT (Alternative Lengthening of Telomeres) activation.[6]
The Epitalon research contains a genuine paradox: while telomere extension is genetically associated with certain cancer risks in population studies, preclinical animal studies with Epitalon show reduced tumor incidence — not increased. Researchers note that how a telomere is maintained (and in what context) matters as much as its length.[7]
FOXO4-DRI takes a different approach to the problem. Rather than optimizing cellular function, it targets and eliminates senescent cells — damaged, dysfunctional cells that have stopped dividing but refuse to die. These cells are sometimes called "zombie cells" because they persist in tissue and continuously secrete pro-inflammatory signals that degrade the surrounding environment.
The accumulation of senescent cells is one of the most well-established hallmarks of biological aging. They create a chronically inflamed tissue environment — exactly the kind of milieu that supports tumor initiation and progression. FOXO4-DRI works as a senolytic peptide, disrupting the survival mechanism that allows senescent cells to persist.
Senescent cells survive by exploiting an interaction between FOXO4 and p53. FOXO4-DRI is a modified peptide that competitively disrupts this interaction, triggering apoptosis in senescent cells while leaving healthy cells intact. Clearing these cells reduces the SASP (Senescence-Associated Secretory Phenotype) — the chronic inflammatory output that promotes disease progression.[8]
What This Actually Means
None of these peptides are approved treatments for cancer, and most of the data comes from preclinical or in vitro models. Human trials are limited, replication outside of original research groups is still developing, and long-term safety profiles are largely unknown.
But what the research collectively illustrates is something worth paying attention to: your biology has internal systems designed to maintain cellular integrity — to suppress uncontrolled growth, clear damaged tissue, maintain DNA stability, and regulate the metabolic environment that cancer either thrives in or can't survive in.
Peptides like these represent an attempt to understand, and eventually support, those systems. That's not a cure. It's a different way of framing what health optimization is actually for.
The goal isn't to cure disease with peptides. The goal is to maintain the biological conditions in which disease struggles to gain a foothold — metabolic balance, mitochondrial health, cellular cleanup, and DNA stability. These four peptides sit at the intersection of longevity research and emerging oncology science. They won't be the last.
References
- 1Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. PMID: 37366315
- 2Marathe SJ et al. Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression. npj Metabolic Health and Disease. 2025;3(1):10. nature.com
- 3PMC Review. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. PMC. 2023. PMC9854231
- 4Yin X et al. Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination. Advanced Science. 2024. PMC11578304
- 5Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590–592. PMID: 12937682
- 6Al-Dulaimi S et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025. PMID: 40908429
- 7The Epitalon Paradox: Longevity Pineal Peptide Challenges Link Between Telomere Extension and Cancer Risk. Intelligent Living. 2025. intelligentliving.co
- 8Baar MP et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017;169(1):132–147. FOXO4-DRI mechanism. PMID: 28340339